Influence of subclinical hyperthyroidism on the cardiovascular system
https://doi.org/10.14341/ket2015233-37
Abstract
Subclinical hyperthyroidism occurs when the serum TSH is below the lower limit of the reference range and the free T4 and T3 concentrations are normal. Тhe clinical significance of subclinical hyperthyroidism is much debated. Subclinical hyperthyroidism has been associated with several biological effects on cardiovascular system, such as increased heart rate, left ventricular mass. Observational studies have reported an association between subclinical hyperthyroidism and coronary heart disease, incident atrial fibrillation, and cardiac dysfunction.
About the Authors
T Y Demidova
Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation
I N Drozdova
Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation
References
1. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch. Intern. Med. 2000; 160(4):526. doi: 10.1001/archinte.160.4.526.
2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J ClinEndocrinol Metab. 2002;87(2):489-499. doi: 10.1210/jcem.87.2.8182
3. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249-1252. doi: 10.1056/nejm199411103311901.
4. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract. 2004;10(6):497-501. doi: 10.4158/ep.10.6.497.
5. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. JAMA. 2004;291(2):228. doi: 10.1001/jama.291.2.228.
6. Wilson GR, Curry RW. Subclinical thyroid disease. Amer Fam Physician. 2005;72(8):1517-1524.
7. Дедов И.И., Мельниченко Г.А. Болезнь Грейвса и эндокринная офтальмопатия. - М.; 2012. [Dedov II, Mel’nichenko GA. Bolezn’ Greivsa i endokrinnaya oftal’mopatiya. Moscow; 2012. (In Russ).]
8. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007;92(1):3-9. doi: 10.1210/jc.2006-2472.
9. Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol / European Federation of Endocrine Societies. 2005;152(1):1-9. doi: 10.1530/eje.1.01809.
10. Ross DS. Subclinical thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott, Williams and Wilkins; 2000; 1016-1020.
11. Papi G, Pearce EN, Braverman LE, et al. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med. 2005;118(4):349-361. doi: 10.1016/j.amjmed.2005.01.004.
12. Cooper DS. Hyperthyroidism. The Lancet. 2003;362(9382):459-468. doi: 10.1016/s0140-6736(03)14073-1.
13. Toft AD. Subclinical hyperthyroidism. N Engl J Med. 2001;345(7): 512-516. doi: 10.1056/NEJMcp010145.
14. Boelaert K. Thyroid hormone in health and disease. J Endocrinol. 2005;187(1):1-15. doi: 10.1677/joe.1.06131.
15. Brownlie BEW, Legge HM. Thyrotropin results in euthyroid patients with a past history of hyperthyroidism. Eur J Endocrinol / European Federation of Endocrine Societies. 1990;122(5):623-627. doi: 10.1530/acta.0.1220623.
16. Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid. 1996;6(5):391-396. doi: 10.1089/thy.1996.6.391.
17. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol / European Federation of Endocrine Societies. 1994;130(4):350-356. doi: 10.1530/eje.0.1300350.
18. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinol Metab Clin N Am. 1998;27(1):37-49. doi: 10.1016/s0889-8529(05)70296-6.
19. Sawin CT. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med. 1991;151(1):165. doi: 10.1001/archinte.1991.00400010159025.
20. Cooper DS. Subclinical thyroid disease: A clinician’s perspective. Ann Intern Med. 1998;129(2):135. doi: 10.7326/0003-4819-129-2-199807150-00016.
21. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85(12):4701-4705. doi: 10.1210/jcem.85.12.7085.
22. Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88(4):1672-1677. doi: 10.1210/jc.2002-021046.
23. Pearce EN, Yang Q, Benjamin EJ, et al. Thyroid function and left ventricular structure and function in the Framingham Heart Study. Thyroid. 2010;20(4):369-373. doi: 10.1089/thy.2009.0272.
24. Dörr M, Ittermann T, Aumann N, et al. Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up. Clin Endocrinol (Oxf). 2010;73(6):821-826. doi: 10.1111/j.1365-2265.2010.03882.x.
25. Petretta M, Bonaduce D, Spinelli L, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol / European Federation of Endocrine Societies. 2001;145(6):691-696. doi: 10.1530/eje.0.1450691.
26. Yavuz H, Altunbag H, Balci M, et al. Normal systolic time intervals in subclinical hyperthyroidism. J Endocrinol Invest. 2000; 23(7; SUPP 1):38-38.
27. Psaltopoulou T, Ilias I, Toumanidis S, et al. Endogenous subclinical hyperthyroidism: Metabolic and cardiac parameters. Eur J Intern Med. 2007;18(5):423-429. doi: 10.1016/j.ejim.2006.12.010.
28. Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on l-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf). 1992;37(6):500-503. doi: 10.1111/j.1365-2265.1992.tb01480.x.
29. Dorr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab. 2006;91(2):530-534. doi: 10.1210/jc.2005-1786.
30. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf). 2006;64(3): 323-329. doi: 10.1111/j.1365-2265.2006.02464.x.
31. Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: A casual or causal association? A systematic literature review. Clin Appl Thromb Hemost. 2010;17(4):387-392. doi: 10.1177/1076029610364521.
32. Volzke H, Robinson DM, Schminke U, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab. 2004;89(5): 2145-2149. doi: 10.1210/jc.2003-031028.
33. Dorr M, Empen K, Robinson DM, et al. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. Eur J Endocrinol. 2008;159(2):145-152. doi: 10.1530/EJE-08-0140.
34. Tenerz Å, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med. 2009;228(3):229-233. doi: 10.1111/j.1365-2796.1990.tb00223.x.
35. Machill K, Scholz GH. Dependence of haemodynamic changes in hypothyroidism on age of patients and etiology hyperthyroidism. In: Braverman E, Eber O, Langsteger W, editors. Heart and thyroid. Wien; 1994. p. 203.
36. Polikar R, Feld GK, Dittrich HC, et al. Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol. 1989;14(4):999-1002. doi: 10.1016/0735-1097(89)90479-8.
37. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5): 838-842. doi: 10.1067/mhj.2001.119370.
38. Gammage MD. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928. doi: 10.1001/archinte.167.9.928.
39. Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab. 2005;90(9):5489-5496. doi: 10.1210/jc.2005-0170.
40. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. The Lancet. 2001;358(9285):861-865. doi: 10.1016/s0140-6736(01)06067-6.
Review
For citations:
Demidova T.Y., Drozdova I.N. Influence of subclinical hyperthyroidism on the cardiovascular system. Clinical and experimental thyroidology. 2015;11(2):33-37. (In Russ.) https://doi.org/10.14341/ket2015233-37
Views:
505
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
